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Objectives This study examined the functionality of high-density lipoprotein (HDL) in individuals with end-stage renal dis-
ease on dialysis (ESRD-HD).
Background The high rate of cardiovascular disease (CVD) in chronic kidney disease is not explained by standard risk factors,
especially in patients with ESRD-HD who appear resistant to benefits of statin therapy. HDL is antiatherogenic
because it extracts tissue cholesterol and reduces inflammation.
Methods Cellular cholesterol efflux and inflammatory response were assessed in macrophages exposed to HDL of pa-
tients with ESRD-HD or controls.
Results HDL from patients with ESRD-HD was dramatically less effective than normal HDL in accepting cholesterol from
macrophages (median 6.9%; interquartile range [IQR]: 1.4% to 10.2%) versus control (median 14.9%; IQR: 9.8%
to 17.8%; p  0.001). The profound efflux impairment was also seen in patients with ESRD-HD and diabetes
compared with patients with diabetes without renal disease (median 8.1%; IQR: 3.3% to 12.9%) versus control
(median 13.6%; IQR: 11.0% to 15.9%; p  0.009). In vitro activation of cellular cholesterol transporters in-
creased cholesterol efflux to both normal and uremic HDL. HDL of patients with ESRD-HD had reduced anti-
chemotactic ability and increased macrophage cytokine response (tumor necrosis factor-alpha, interleukin-6,
and interleukin-1-beta). HDL of patients with ESRD-HD on statin therapy had reduced inflammatory response
while maintaining impaired cholesterol acceptor function. Interestingly, impaired HDL-mediated efflux did not
correlate with circulating C-reactive protein levels or cellular inflammatory response.
Conclusions These findings suggest that abnormal HDL capacity to mediate cholesterol efflux is a key driver of excess CVD in
patients on chronic hemodialysis and may explain why statins have limited effect to decrease CV events. The
findings also suggest cellular cholesterol transporters as potential therapeutic targets to decrease CV risk in this
population. (J Am Coll Cardiol 2012;60:2372–9) © 2012 by the American College of Cardiology Foundation
Published by Elsevier Inc. http://dx.doi.org/10.1016/j.jacc.2012.09.013Chronic kidney disease (CKD) dramatically increases car-
diovascular disease (CVD) risk, which escalates with declin-
ing kidney function and is maximal in patients with end-
stage renal disease on chronic hemodialysis (ESRD-HD)
(1–3). Although increased CV mortality in patients with
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accepted September 5, 2012.ESRD-HD is attributable to many causes, death from
atherosclerotic coronary artery disease is persistently higher
than that in the general population, even after adjustments
for traditional CVD risk factors (2–6). Patients with
ESRD-HD are also unique in their diminished benefit from
statin interventions that are effective in reducing CVD risk
in other high-risk patients (7–9). The recent SHARP (Study
of Heart and Renal Protection) trial reported decreased
See page 2380
numbers of CV events with aggressive cholesterol lowering
using simvastatin and ezetimibe, in patients with CKD
(9,10). Results were overall positive, but the difference in the
ESRD-HD subgroup was too small to show statistical
significance. The lack of benefit of aggressive lipid-lowering
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December 11, 2012:2372–9 HDL Is Defective in ESRDtherapy in ESRD suggests other mechanisms, such as low
levels of high-density lipoprotein (HDL). HDL has gener-
ated considerable interest as a target for interventions to
decrease atherosclerotic burden (11–13). One key function
of HDL, namely macrophage cholesterol efflux capacity
(14–18), was inversely associated with measures of carotid
and coronary atherosclerosis in a non-CKD population, inde-
pendent of HDL concentration (18).
Interestingly, Holzer et al. (14) recently reported reduced
efflux ability of HDL in patients with ESRD-HD compared
with HDL from controls without kidney disease. Although
intriguing, these data did not examine whether coexisting
comorbidities such as diabetes, obesity, underlying CVD, and
certain demographic characteristics of patients with ESRD-HD
(e.g., age, sex, race, underlying CKD) contributed to the
observed differences. It is critically important to determine the
mechanisms by which abnormalities in HDL function
predispose patients with CKD to increased atherosclerotic
burden to develop rational therapeutic strategies. In this
study, we evaluated the ability of HDL from patients with
ESRD-HD to elicit cholesterol efflux and modulate inflam-
matory responses in macrophages and compared this with
HDL from individuals with normal kidney function with
similar coexisting clinical and demographic characteristics
that influence development of atherosclerotic CVD (19).
Methods
Participants and study design. Adult patients with ESRD
undergoing maintenance hemodialysis at Vanderbilt Uni-
versity Medical Center (VUMC) for more than 3 months
were studied (n  29). Control participants (n  28) with
ormal renal function who did not differ from the patients
n age, sex, race, presence of diabetes mellitus, history of
VD (angina, myocardial infarction, stroke/transient ische-
ic attack), and use of statin and angiotensin-converting
nzyme inhibitors (ACEIs)/angiotensin receptors blockers
ARBs) were recruited from the general medicine outpatient
linic at VUMC. Exclusion criteria included pregnancy and
urrent smoking. The study protocols were approved by the
nstitutional review board at VUMC, and all participants
ave informed consent.
ssessment of plasma lipid profile and C-reactive protein
nd isolation of lipoproteins. Blood was taken after an
vernight fast (prior to hemodialysis) in K2 ethylenediamine
etraacetic acid–containing tubes and centrifuged at 1,700 g
or 15 min. Plasma levels of total cholesterol, triglycerides, and
DL were measured enzymatically (Cliniqa, San Marcos,
alifornia). High-sensitivity C-reactive protein (hsCRP) was
easured using a high-sensitivity immunoturbidimetric assay
Roche Modular Systems, Indianapolis, Indiana) (20). The
polipoprotein B (apoB)–containing fraction (d  1.006 to
1.063 g/ml) and HDL fraction (d  1.063 to 1.21 g/ml)
were isolated from fresh plasma by sequential density
ultracentrifugation after density adjustment with potassium
bromide (21). The purity of the isolation was checked by the QQuickGel lipoprotein electro-
phoresis system (Helena Labora-
tories, Beaumont, Texas).
Macrophage assays of choles-
terol uptake with apoB fraction
and cholesterol efflux with
HDL. THP-1 cells (American
Type Culture Collection, Ma-
nassas, Virginia) were plated
onto 35-mm wells and differen-
tiated into macrophages by
RPMI containing 10% fetal bo-
vine serum and 50 ng/ml phorbol
12-myristate 13-acetate. For up-
take studies, THP-1 macro-
phages were exposed to the apoB
fraction (50 g/ml) from pa-
tients with ESRD-HD or con-
trols for 24 h. For efflux studies,
THP-1 macrophages were cho-
lesterol enriched with acetylated
low-density lipoprotein (LDL)
(100 g/ml, Intracel, Frederick,
aryland) and exposed to HDL
50 g/ml) and lipopolysaccha-
ide (LPS) (50 ng/ml, Sigma-Aldrich Co., St. Louis,
issouri) for 24 h. In some studies, liver X receptor (LXR)
gonist T0901317 (1 M, Sigma-Aldrich) was added to
activate ATP-binding cassette (ABC) transporters. Cellular
cholesterol content was measured by gas chromatography
(21,22). Cholesterol efflux was determined as the percent
decrease in cellular cholesterol content at baseline versus
after incubation with HDL (15,23). Cell proteins were
solubilized by addition of 0.1 N NaOH and protein content
was measured by bicinchoninic acid assay.
Macrophage chemotaxis assay and inflammatory reaction
with HDL. Macrophage migrating activity used THP-1
cells exposed to HDL from patients with ESRD-HD or
controls. The studies were performed in a microchemotaxis
chamber in which the upper and lower compartments are
separated by an uncoated polycarbonate filter (Neuroprobe,
Gaithersburg, Maryland). THP-1 cells (5  105/well) were
exposed to HDL (50 g/ml) for 1 h and then added to the
upper compartment. Monocyte chemotactic protein
(MCP)-1 0.1 g/ml (Preprotech, Rocky Hill, New Jersey)
as added to the lower compartment. Filters were fixed in
ethanol and stained with 1% crystal violet, and the
igrated cells were counted under the microscope. Dupli-
ate wells were used for each experimental condition, and 5
elds (40) were counted for each well. The anti-
nflammatory function of HDL was measured as the cyto-
ine response in LPS-activated macrophages. THP-1 mac-
ophages were exposed to HDL (50 g/ml) and LPS (50
g/ml) for 4 to 24 h. Total RNA was extracted from cells
ith the RNeasy mini kit (Qiagen, Valencia, California).
Abbreviations
and Acronyms
ABC  ATP-binding
cassette
apoB  apolipoprotein B
CKD  chronic kidney
disease
CVD  cardiovascular
disease
ESRD-HD  end-stage renal
disease on chronic
hemodialysis
HDL  high-density
lipoprotein
hsCRP  high-sensitivity
C-reactive protein
IL  interleukin
LDL  low-density
lipoprotein
LXR  liver X receptor
MCP  monocyte
chemotactic protein
TNF  tumor necrosis
factoruantification of human interleukin (IL)-1-beta, IL-6,
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HDL Is Defective in ESRD December 11, 2012:2372–9tumor necrosis factor (TNF) alpha, and endogenous control
human Euk 18S rRNA levels was performed by real-time
reverse transcriptase polymerase chain reaction (PCR) using
a Prism 7700 sequence detection system (Applied Biosys-
tems, Inc., Foster City, California). Probes for IL-1-beta
(Hs99999029_m1), IL-6 (Hs99999032_m1), TNF-alpha
(Hs99999043_m1), and 18S rRNA were obtained from
Applied Biosystems.
Statistical analysis. The sample size was calculated using
published results showing 11  3% as mean value and
tandard deviation for cholesterol efflux to normal HDL
18). To detect a 25% difference, we estimated 26 partici-
ants per arm to achieve 90% statistical power with a
-sided significance level of 5%. Results are expressed as a
ean of triplicate assays. Descriptive statistics are presented
s frequencies and percentages for categorical variables and
ean  SD or median (interquartile range [IQR]) accord-
ng to the distribution of the continuous variables. Demo-
raphic and clinical factors were compared between patients
ith ESRD-HD and controls using the Wilcoxon rank sum
est or Pearson chi-square test, as appropriate. Correlation
etween efflux and mRNA expression of inflammatory
arameters (hsCRP, IL-1-beta, IL-6, and TNF-alpha) was
ssessed with the Spearman rank correlation test separately
or patients with ESRD and controls. One-way analysis of
ariance was used to examine the relationships between the
igrated cells and disease status. Post hoc pairwise com-
arisons among the groups were done only if the analysis of
ariance was statistically significant. The adjusted difference
n efflux between patients with ESRD-HD and controls was
ssessed using multivariable linear regression models with
djustment for age, sex, race, body mass index (BMI),
iabetes, statin usage, hsCRP, total cholesterol, triglycer-
des, HDL, LDL, CVD, and ACEI/ARB usage. To avoid
verfitting by including too many variables into a linear
egression, sex, race, hsCRP, total cholesterol, triglycerides,
Characteristics of Study ParticipantsTable 1 Characteristics of Study Participan
N
Con
(n 
Age, yrs 57 46
Sex, % male 57
Race, % white 57
Body mass index, kg/m2 57 31.2
Diabetes mellitus, % 57
Cardiovascular disease, % 57
Statin usage, % 57
ACEI/ARB, % 57
hsCRP, mg/dl 56 1.1 (0
Total cholesterol, mg/dl 56 198
Triglycerides, mg/dl 56 95 (7
HDL, mg/dl 56 40.6
LDL, mg/dl 56 139
Values are mean  SD or %. The Wilcoxon rank sum test was used fo
using the chi-square test.ACEI  angiotensin-converting enzyme inhibitor; ARB  angiotensin r
hemodialysis; HDL  high-density lipoprotein; hsCRP  high-sensitivity C-reaHDL, LDL, CVD, and ACEI/ARB usage were combined
through a propensity score. The propensity score was
computed as the logit of a logistic regression in which the
outcome variable was ESRD-HD versus control, including
the set of covariates listed above as explanatory variables.
The final multivariable linear regression included the
ESRD-HD variable, age, BMI, diabetes status, statin
usage, and the propensity score. Multivariable linear
regression assumptions of normality of residuals were
checked and were met (24). Concentrations of hsCRP,
IL-6, IL-1-beta, and TNF-alpha were transformed by
natural logarithm to improve normality. Statistical anal-
yses were performed using R version 2.10.0. A 2-sided
significance level of 5% was required for consideration as
statistically significant.
Results
Characteristics of study participants. There were no sta-
tistically significant differences between patients with
ESRD-HD and controls in any of the demographic or
comorbidity variables, except that patients with ESRD-HD
had significantly elevated plasma hsCRP levels (p  0.001)
(Table 1). There were no statistically significant differences
in total cholesterol, triglyceride, and HDL levels between
patients with ESRD-HD and controls.
Macrophage uptake of apoB lipoproteins. Because foam
cell formation reflects an imbalance between lipoprotein
uptake and cholesterol efflux, we evaluated the macrophage
cholesterol-loading capacity of apoB-containing lipoprotein
fractions. ApoB fractions isolated from patients with
ESRD-HD and controls caused similar degrees of choles-
terol accumulation in THP-1 macrophages (38.0  5.0
g/mg vs. 34.4  5.5 g/mg protein in controls and
atients with ESRD-HD, respectively; p  0.19).
Patients With ESRD-HD
(n  29) p Value
48 10 0.51
52 0.22
34 0.36
31.6 7.9 0.66
48 0.90
34 0.71
31 0.84
34 0.85
) 6.2 (3.1,17.7) 0.001
170 35 0.12
) 102 (75,135) 0.84
36.9 17.2 0.08
110 31 0.24
aring continuous variables, and categorical variables were comparedts
trols
28)
 11
36
46
 7.2
50
39
29
32
.6,5.1
 66
3,124
 9.9
 64
r compeceptor blocker; ESRD-HD  end-stage renal disease on chronic
ctive protein; LDL  low-density lipoprotein.
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December 11, 2012:2372–9 HDL Is Defective in ESRDEfflux capacity of HDL. Cholesterol acceptor function
rom cholesterol-loaded THP-1 cells was significantly lower
or HDL of patients with ESRD-HD (median 6.9%; IQR:
.4% to 10.2%) versus control (median 14.9%; IQR: 9.8% to
7.8%; p  0.001) and remained significantly lower in
atients with ESRD-HD after adjustment for age, sex, race,
MI, diabetes, hsCRP, total cholesterol, triglycerides,
DL, LDL, CVD, and use of statins or ACEIs/ARBs
difference 10.2%; 95% confidence interval [CI]: 5.8% to
4.5%; p  0.0001) (Fig. 1). Even within the diabetic
ubgroup, the HDL of patients with ESRD-HD and diabetes
ad reduced efflux capacity compared with HDL efflux capac-
ty of controls with normal renal function and diabetes (median
.1%; IQR: 3.3% to 12.9%) versus control (median 13.6%;
QR: 11.0% to 15.9%; p 0.009) (Online Fig. 1). Statin usage
id not improve HDL efflux capacity in patients with
SRD-HD (median 6.8%; IQR: 1.8% to 8.8% versus median
.8%; IQR: 1.4% to 10.5% for statin users and nonusers,
espectively).
To assess whether activation of cellular transporters can
ffect the acceptor capacity of HDL, we exposed THP-1
ells to an LXR agonist (T0901317), which increased
xpression of ABCA1 by 21.4-fold and ABCG1 by 2.7-fold
p  0.001 for each). Up-regulation in cellular ABCA1/G1
levels significantly increased cholesterol efflux to HDL of
both controls and patients with ESRD-HD to a similar
extent (Fig. 2).
Figure 1 Efflux to HDL From Patients With ESRD-HD
and Controls With Normal Kidney Function
Unadjusted p values from the Wilcoxon rank sum test. Adjusted p values from
multivariable regression analysis with adjustment for age, sex, race, body
mass index, diabetes, high-sensitivity C-reactive protein, total cholesterol, trig-
lycerides, high-density lipoprotein (HDL), low-density lipoprotein, cardiovascular
disease, and use of statins or angiotensin-converting enzyme inhibitors/angio-
tensin receptor blockers. ESRD-HD  end-stage renal disease on chronic
hemodialysis.Inflammatory capacity of HDL. Compared with the cy-
tokine response observed in LPS-exposed THP-1 cells
treated with HDL of controls, HDL isolated from patients
with ESRD-HD caused a greater inflammatory response
(Fig. 3A). However, the cytokine response to HDL from
the subgroup of patients with ESRD-HD on statin therapy
was not different than that of controls taking statins
(Fig. 3B). In addition, although HDL from controls re-
duced MCP1-induced migration of THP-1 macrophages,
HDL from patients with ESRD-HD provided no anti-
chemotactic effect (Online Fig. 2).
Macrophage cholesterol efflux correlations with systemic
and cellular inflammation. In view of the link between
cholesterol handling and inflammation in atherogenesis, we
evaluated the correlation between individual macrophage
cholesterol efflux capacity of HDL and markers of systemic
inflammation and inflammatory response of macrophages.
Efflux and circulating levels of hsCRP or macrophage
inflammatory response did not show a statistically signifi-
cant correlation within either controls or patients with
ESRD-HD (Table 2).
Discussion
Our data indicated that HDL isolated from patients with
ESRD on maintenance hemodialysis had markedly im-
paired capacity to elicit cholesterol efflux while potentiating
inflammation in macrophages compared with HDL isolated
from matched individuals with similar clinical and demo-
graphic characteristics but with normal kidney function.
Within ESRD, HDL of statin-taking individuals did not
have improved cholesterol acceptor capacity, although the
proinflammatory effects were less, thus suggesting that
Figure 2 Efflux With or Without Activation of
ABC Transporters by LXR Agonist to HDL
p values from the Wilcoxon rank sum test. ABC  ATP-binding cassette;
LXR  liver X receptor; other abbreviations as in Figure 1.different HDL functions do not respond similarly to ther-
2376 Yamamoto et al. JACC Vol. 60, No. 23, 2012
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lesterol handling and regulation of vascular inflammation,
both atheroprotective markers of HDL function, do not
track together within a given individual with advanced
uremia. This impaired cholesterol acceptor capacity of
dysfunctional HDL is a potential novel mechanism to
explain the exponentially increased CVD risk and lack of
response to conventional treatment strategies in patients
with advanced uremia. Instead, our findings that pharma-
Figure 3 Proinflammatory Effects of HDL From Patients With E
(A) Cytokine response of lipopolysaccharide (LPS)-exposed THP-1 macrophages to
cells exposed to LPS alone. (B) Cytokine response to HDL from statin-using patien
alone. p value from the Wilcoxon rank sum test. IL  interleukin; TNF  tumor necological up-regulation of cellular expression of ABCA1and ABCG1 significantly increased efflux to control HDL
as well as to the dysfunctional HDL of patients with
ESRD-HD suggested the potential for cholesterol trans-
porters as a novel target to lessen CVD in this population.
Although accelerated atherosclerosis and increased num-
bers of CV events have been extensively documented in
CKD, the pathophysiological mechanisms are complex and
not explained by traditional risk factors, especially in
ESRD-HD (2,4–6). Although many of our patients with
D and Controls
rom patients with ESRD-HD and controls not using statins expressed relative to
h ESRD-HD and controls expressed relative to response of cells exposed to LPS
factor; other abbreviations as in Figure 1.SRD-H
HDL f
ts wit
crosisESRD-HD had diabetes, the extreme impairment in efflux
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December 11, 2012:2372–9 HDL Is Defective in ESRDcapacity of HDL was attributable to uremia and not affected
by diabetes mellitus per se. These findings echo previous
studies that showed that advanced uremia is the single most
important amplifier of CVD in various populations, includ-
ing those with diabetes mellitus (25–27). In a recent study,
HDL from patients on chronic hemodialysis had reduced
cholesterol efflux capacity compared with HDL from a
control group (14). However, whereas the study group
contained patients with diabetes and individuals on statin
therapy, the control group was composed of healthy partic-
ipants without diabetes, hyperlipidemia, or statin therapy.
Thus, potential effects of these confounders on HDL
dysfunction could not be teased out. In the current study, by
considering coexisting comorbidities such as diabetes, obe-
sity, underlying CVD, and relevant demographic character-
istics of patients with ESRD-HD such as age, sex, and race,
our results demonstrated the overarching impact of the
uremic milieu on HDL’s decreased capacity for cholesterol
efflux.
The relevance of HDL efflux capacity to the pathogenesis
of atherosclerosis relates to the central role of HDL in
reverse cholesterol transport, which removes excess choles-
terol from peripheral cells and transports it in plasma for
hepatic delivery, excretion in bile, and intestinal loss (16,17).
HDL can adversely impact CVD risk in ESRD through
several mechanisms. In our study, the trend for lower HDL
level in our patients with ESRD-HD did not reach signif-
icance. However, circulating levels of HDL do not predict
all-cause or CV mortality in patients with ESRD-HD (28).
In our study, equal amounts of HDL were used to deter-
mine cholesterol efflux capacity. We showed that patients
on hemodialysis have dysfunctional HDL with impaired
macrophage cholesterol efflux. Our data showed that statin
treatment of patients with ESRD-HD did not improve the
cholesterol efflux capacity of their HDL. Indeed, cholesterol
efflux capacity was also not affected in a clinical study of
HDL function of patients without CKD treated with statins
(18). Together, these observations parallel the recent appre-
ciation that lipid-lowering therapies provide only limited
benefits against CVD and that HDL function may explain
the substantial residual risk in patients receiving standard of
care (29,30).
Our data also made clear the important new observation
that functionality of uremic HDL can be improved. Up-
Correlation Between CholesterolEfflux and Inflammatory MarkersAmong Patients With ESRD-HD and Controls
Table 2
Corr lation B twe n Cholesterol
Efflux and Inflammatory Markers
Among Patients With ESRD-HD and Controls
Inflammation Marker Controls Rho Patients With ESRD-HD Rho
hsCRP 0.2088 0.0257
TNF-alpha 0.0698 0.1642
Interleukin-6 0.2313 0.0417
Interleukin-1-beta 0.2698 0.0195
Rho: Spearman correlation coefficients.
TNF  tumor necrosis factor; other abbreviations as in Table 1.regulation of ABCA1 and ABCG1 transporters by LXRactivation significantly increased efflux not only to control
HDL but also to the dysfunctional HDL of patients with
ESRD-HD (Fig. 2). These findings raise the interesting
possibility that, even in the face of dysfunctional HDL,
activation of cellular transporters can abrogate a proathero-
genic pathway and cause CVD risk reduction in this
population. The biological and therapeutic relevance of
these findings is underscored by our preliminary data that
monocytes of patients with ESRD-HD have reduced ex-
pression of cellular ABCA1 and scavenger receptor BI
compared with cells from controls (V. Kon, unpublished
data, 2012). These observations complement findings that
in scavenger receptor BI–expressing Chinese hamster ovary
cells, efflux to uremic HDL was significantly reduced
compared with control HDL (14).
In addition to cholesterol handling, HDL has anti-
inflammatory properties (31). Among patients with ESRD-
HD, individuals with proinflammatory HDL showed more
comorbidities and increased risk of CV and all-cause mor-
talities than individuals with anti-inflammatory HDL (19).
Our results showed that macrophage expression of IL-1-
beta, IL-6, and TNF-alpha was greater with uremic HDL
compared with HDL from controls. A tendency for greater
cytokine response in statin-using controls than those with-
out statin treatment is consistent with the fact that most
participants within the statin-using control subgroup had a
previous history of CVD, known to enhance inflammation
in the non-CKD population (32). We also found that
uremic HDL did not reduce MCP-1–induced chemotaxis.
This is consistent with observations that HDL interacts
with macrophage cholesterol transporters to modulate ex-
pression of MCP1 and chemotaxis (33,34). This disrupted
inflammatory response of uremic HDL (35) may enhance
recruitment of monocytes into the subendothelial space.
Whether specific cellular phenotypes or cytokines underlie
accelerated atherogenesis and acute CVD events in
ESRD-HD remains to be clarified. Also unclear is the
contribution of ESRD-specific metabolic abnormalities,
such as those in calcium and phosphate transport. Interest-
ingly, sevelamer, a resin that binds dietary phosphate and
lessens experimental atherosclerosis (36), decreased mortal-
ity in patients on hemodialysis in association with improved
arterial stiffness and increased levels of HDL (37).
We next evaluated the association between anti-
inflammatory and lipid-handling properties of a given HDL
sample (Table 2). We found that these functionalities did
not track together in individual patients. Although unex-
pected, the results do not negate the importance of either
inflammation or abnormal lipid handling in ESRD. Instead,
the findings raise the intriguing possibility of separate and
distinct mechanistic pathways for different functions of
HDL that may involve compositional changes in specific
HDLs. For example, reactive lipid peroxidation products
such as malondialdehyde (MDA) modify and cross-link
specific residues in apoAI, causing distinct functional con-
sequences (38,39). Interestingly, although progressive de-
2378 Yamamoto et al. JACC Vol. 60, No. 23, 2012
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is currently not known if MDA or other peroxidation
products contribute to impairment in HDL’s anti-
inflammatory function or influence levels or activity of
antioxidant enzymes such as paraoxonase (41). These find-
ings also suggest that reduced HDL ability to mediate
cholesterol efflux may be the key driver for excess CVD
among patients with ESRD and that correction of both
cholesterol handling and inflammation must be remedied to
achieve a therapeutic benefit in this population.
Study limitations. The sample size was small and from a
single institution, which limits generalizability. On the other
hand, patients with ESRD-HD and controls were well
matched, which is a unique strength. Nevertheless, we were
not able to account for all confounders that might be present in
these patients. The results are associative and do not prove a
cause and effect relationship, which should be tested in
future studies. We did not relate cholesterol efflux to direct
CVD events and view this as an important next step.
Finally, ESRD alters several lipid and protein components
of HDL, including enrichment in the acute phase reactant,
serum amyloid A (14,42,43). Thus, the specific functional
impact of uremia-associated HDL compositional changes
on particular functions remains an important area for future
investigations.
Conclusions
Patients on maintenance hemodialysis have abnormal HDL
with impaired cholesterol acceptor function and proinflam-
matory effects. HDL from individuals in dialysis taking
statins becomes anti-inflammatory but maintains a reduced
capacity for cholesterol efflux. Improved cholesterol efflux to
HDL of patients with ESRD-HD is instead achieved by
activation of cellular cholesterol transporters via LXR, which
suggests a novel target for therapeutic interventions in this
population.
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